463 related articles for article (PubMed ID: 23414309)
1. Histone deacetylases as targets for treatment of multiple diseases.
Tang J; Yan H; Zhuang S
Clin Sci (Lond); 2013 Jun; 124(11):651-62. PubMed ID: 23414309
[TBL] [Abstract][Full Text] [Related]
2. Targeting histone deacetylases for cancer therapy: from molecular mechanisms to clinical implications.
Li Z; Zhu WG
Int J Biol Sci; 2014; 10(7):757-70. PubMed ID: 25013383
[TBL] [Abstract][Full Text] [Related]
3. Focus on acetylation: the role of histone deacetylase inhibitors in cancer therapy and beyond.
Konstantinopoulos PA; Karamouzis MV; Papavassiliou AG
Expert Opin Investig Drugs; 2007 May; 16(5):569-71. PubMed ID: 17461732
[TBL] [Abstract][Full Text] [Related]
4. Epigenetic modulation and understanding of HDAC inhibitors in cancer therapy.
Ramaiah MJ; Tangutur AD; Manyam RR
Life Sci; 2021 Jul; 277():119504. PubMed ID: 33872660
[TBL] [Abstract][Full Text] [Related]
5. The role of histone deacetylases (HDACs) in human cancer.
Ropero S; Esteller M
Mol Oncol; 2007 Jun; 1(1):19-25. PubMed ID: 19383284
[TBL] [Abstract][Full Text] [Related]
6. Natural Product Inhibitors of Histone Deacetylases as New Anticancer Agents.
Hanikoglu A; Hanikoglu F; Ozben T
Curr Protein Pept Sci; 2018; 19(3):333-340. PubMed ID: 28059044
[TBL] [Abstract][Full Text] [Related]
7. Protein deacetylases: enzymes with functional diversity as novel therapeutic targets.
Yoshida M; Shimazu T; Matsuyama A
Prog Cell Cycle Res; 2003; 5():269-78. PubMed ID: 14593721
[TBL] [Abstract][Full Text] [Related]
8. Histone deacetylases: target enzymes for cancer therapy.
Mottet D; Castronovo V
Clin Exp Metastasis; 2008; 25(2):183-9. PubMed ID: 18058245
[TBL] [Abstract][Full Text] [Related]
9. Concept of histone deacetylases in cancer: Reflections on esophageal carcinogenesis and treatment.
Schizas D; Mastoraki A; Naar L; Spartalis E; Tsilimigras DI; Karachaliou GS; Bagias G; Moris D
World J Gastroenterol; 2018 Nov; 24(41):4635-4642. PubMed ID: 30416311
[TBL] [Abstract][Full Text] [Related]
10. Histone Deacetylase Inhibitors as Anticancer Drugs.
Eckschlager T; Plch J; Stiborova M; Hrabeta J
Int J Mol Sci; 2017 Jul; 18(7):. PubMed ID: 28671573
[TBL] [Abstract][Full Text] [Related]
11. Molecular pathways: old drugs define new pathways: non-histone acetylation at the crossroads of the DNA damage response and autophagy.
Botrugno OA; Robert T; Vanoli F; Foiani M; Minucci S
Clin Cancer Res; 2012 May; 18(9):2436-42. PubMed ID: 22512979
[TBL] [Abstract][Full Text] [Related]
12. Histone Deacetylases in Kidney Physiology and Acute Kidney Injury.
Hyndman KA
Semin Nephrol; 2020 Mar; 40(2):138-147. PubMed ID: 32303277
[TBL] [Abstract][Full Text] [Related]
13. Histone Deacetylases (HDACs): Evolution, Specificity, Role in Transcriptional Complexes, and Pharmacological Actionability.
Milazzo G; Mercatelli D; Di Muzio G; Triboli L; De Rosa P; Perini G; Giorgi FM
Genes (Basel); 2020 May; 11(5):. PubMed ID: 32429325
[TBL] [Abstract][Full Text] [Related]
14. HDACi--going through the mechanisms.
Wanczyk M; Roszczenko K; Marcinkiewicz K; Bojarczuk K; Kowara M; Winiarska M
Front Biosci (Landmark Ed); 2011 Jan; 16(1):340-59. PubMed ID: 21196174
[TBL] [Abstract][Full Text] [Related]
15. Targeting Histone Deacetylases in Idiopathic Pulmonary Fibrosis: A Future Therapeutic Option.
Korfei M; Mahavadi P; Guenther A
Cells; 2022 May; 11(10):. PubMed ID: 35626663
[TBL] [Abstract][Full Text] [Related]
16. Recent advances in histone deacetylase targeted cancer therapy.
Hoshino I; Matsubara H
Surg Today; 2010 Sep; 40(9):809-15. PubMed ID: 20740342
[TBL] [Abstract][Full Text] [Related]
17. The emerging roles of HDACs and their therapeutic implications in cancer.
Hai R; Yang D; Zheng F; Wang W; Han X; Bode AM; Luo X
Eur J Pharmacol; 2022 Sep; 931():175216. PubMed ID: 35988787
[TBL] [Abstract][Full Text] [Related]
18. Targeting histone deacetylases: development of vorinostat for the treatment of cancer.
Richon VM
Epigenomics; 2010 Jun; 2(3):457-65. PubMed ID: 22121904
[TBL] [Abstract][Full Text] [Related]
19. Selective inhibitors of zinc-dependent histone deacetylases. Therapeutic targets relevant to cancer.
Kollar J; Frecer V
Curr Pharm Des; 2015; 21(11):1472-502. PubMed ID: 25382430
[TBL] [Abstract][Full Text] [Related]
20. Exploiting histone deacetylases for cancer therapy: from hematological malignancies to solid tumors.
Huang M; Geng M
Sci China Life Sci; 2017 Jan; 60(1):94-97. PubMed ID: 27888384
[No Abstract] [Full Text] [Related]
[Next] [New Search]